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Abstract
Background: The clinical significance of tumor-stroma ratio (TSR) has been examined in many tumors. Here we
systematically reviewed all studies that evaluated TSR in head and neck cancer.
Methods: Four databases (Scopus, Medline, PubMed and Web of Science) were searched using the term tumo(u)r-
stroma ratio. The preferred reporting items for systematic reviews and meta-analyses (PRISMA) were followed.
Results: TSR was studied in nine studies of different subsites (including cohorts of nasopharyngeal, oral, laryngeal
and pharyngeal carcinomas). In all studies, TSR was evaluated using hematoxylin and eosin staining. Classifying
tumors based on TSR seems to allow for identification of high-risk cases. In oral cancer, specifically, our meta-
analysis showed that TSR is significantly associated with both cancer-related mortality (HR 2.10, 95%CI 1.56–2.84)
and disease-free survival (HR 1.84, 95%CI 1.38–2.46).
Conclusions: The assessment of TSR has a promising prognostic value and can be implemented with minimum
efforts in routine head and neck pathology.
Keywords: Head and neck cancer, Tumor-stroma ratio, Tumor-stroma, Clinical relevance, Marker, Systematic review
and meta-analysis
Background
Head and neck cancer constitutes a major health prob-
lem in many countries. Squamous cell carcinoma of the
head and neck is the most common tumor in this ana-
tomic region. About 60% of cancers in this region are di-
agnosed at an advanced stage (III-IV), which associates
with poor prognosis [1]. Tissues of head and neck can-
cer, like other solid cancers, consist of both carcinoma
cells and stroma cells. The current management of these
tumors depends widely on TNM stage and WHO histo-
logic grade, which sometimes fails to identify aggressive
tumors especially at an early stage (I-II) of head and
neck cancer. Of note, both TNM stage and WHO grade
take into consideration cancer-related, but not stromal-
related characteristics.
Analysis of prognostic markers expressed in tumor
stroma has received more attention during the last dec-
ade. In recent studies the stroma of head and neck can-
cer has been analyzed mainly for specific molecules such
as alpha-smooth muscle actin [2–5], which requires add-
itional staining that is not routinely requested in daily
clinical practice. For an ideal and practical prognostic
marker, it is a great advantage that it can be assessed on
routinely stained hematoxylin and eosin (HE) slides.
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Interestingly, tumor-stroma ratio (TSR), defined as the
proportion of tumor tissue relative to surrounding stro-
mal tissue, has been recently introduced as a valuable
prognostic feature in many solid tumors [6–9]. In head
and neck cancer, TSR (Fig. 1) has recently been intro-
duced in different subsites as a promising prognostic
feature [10–15]. However, in daily practice, the prognos-
tic implication of TSR in patients with head and neck
cancer remains less well recognized.
The aim of this study is to systematically search the
literature for studies that have examined the significance
of TSR in head and neck cancer. We also highlight the
clinical relevance of TSR as an emerging prognostic
marker that can be included in routine clinical practice.
Recent recommendations [16] for the assessment of TSR
are also briefly discussed.
Methods
Search strategy
Tumo(u)r-stroma ratio was used as a search word to re-
trieve any articles on this prognostic factor. The search
included databases of Scopus, Medline, PubMed and
Web of Science (all years until October 2020). Hits re-
trieved from this search were refined using the following
terms: head and neck squamous cell carcinoma, head
and neck cancer, oral cancer, oropharyngeal cancer, la-
ryngeal cancer, nasopharyngeal cancer, hypopharyngeal
cancer and sinonasal cancer. We included original re-
ports, studies in English language and patient cohort
studies. Therefore, review papers, studies in another lan-
guage than English, and studies on animal samples were
excluded.
Two independent researchers (A.A. & R.A.) conducted
the search and screening processes which were followed
by a discussion between the two researchers to ensure
that all included studies met with the inclusion and ex-
clusion criteria of the present study. The Preferred
Reporting Items for Systematic Review and Meta-
Analysis (PRISMA) were followed [17]. In addition,
REporting recommendations for tumor MARKer prog-
nostic studies (REMARK) guidelines [18] were consid-
ered when assessing the quality of the relevant studies.
Further, Quality In Prognosis Studies (QUIPS) tool [19]
was used to assess risk of bias in the relevant studies.
Statistical analysis
The statistical software R (version 3.6.3) was used to run
an inverse-variance weighted fixed-effect meta-analysis
as implemented in the ‘meta’ package. Due to a small
number of studies, we did not run a random-effect ana-
lysis. In addition to the meta-analyzed hazard ratios (HR),
we also reported the estimated proportion of variation in
effect sizes that was due to heterogeneity (I2) [20].
Results
Search results
A total of 840 records were retrieved initially. After de-
leting duplicates and irrelevant papers, we found nine
studies (Table 1) eligible to be included in this system-
atic review as they had analyzed tumor-stroma ratio
(TSR) in head and neck cancer. The selection process of
the articles is shown with PRISMA flowchart (Fig. 2).
The included studies generally have low risks of bias
(Table 2), and the quality of the included studies is gen-
erally acceptable to high.
Of the nine studies included, one study considered
TSR as an independent predictor for survival in naso-
pharyngeal cancer [11], five studies in oral squamous cell
carcinoma [10, 12–14, 23], and three studies in laryngeal
and pharyngeal squamous cell carcinomas [15, 21, 22]. A
very good or perfect agreement between the observers in
the assessment of TSR has been widely reported in the
published studies [10–14], and it indicates a promising
reproducibility. In the published studies [10–12, 14, 15],
Fig. 1 Hematoxylin and eosin-stained sections of oral squamous cell carcinoma. a: Tumor with a low proportion of stroma (< 50%). b: Tumor
with a high proportion of stroma (≥ 50%) that associated with presence of tumor budding (i.e. small clusters of cancer cells) in a deeply
invaded tumor
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the samples were first scanned at low magnification to
select the field with the highest amount of stroma and
with tumor islands in all sides, and then this field is esti-
mated at a higher magnification of × 100. It was noted
that areas with high stroma (i.e. stroma-rich) were com-
monly near the area of deepest tumor infiltration [11,
12]. A cutoff point of 50% was widely used in the rele-
vant studies (Table 1) to divide the cases into risk groups
and the tumors were considered as either stroma-low
(proportion of stroma < 50%) or stroma-high (propor-
tion of stroma ≥50%).
Prognostic significance of TSR in head and neck cancer
Our meta-analysis of studies of oral cavity cancer (that
was the most analyzed subsite), showed statistically sig-
nificant association between TSR and survival (Fig. 3).
We found that tumors with a high amount of stroma
were associated with worse disease-specific survival with
a hazard ratio (HR) of 2.10 and 95% confidence interval
(CI) of 1.56 to 2.84 (Fig. 3a). In addition, such tumors
were associated with worse disease-free survival (HR
1.84, 95%CI 1.38–2.46; Fig. 3b). In the meta-analysis, we
observed some heterogeneity between the studies of
disease-specific survival (I2 = 59%) but no heterogeneity
(I2 = 0) between the studies of disease-free survival.
Although we were not able to conduct meta-analyses
for the other subsites of head and neck (nasopharynx,
pharynx, and larynx) due to the limited number of stud-
ies, the available studies reported promising predictive
power of TSR as summarized in Table 1. For example,
Zhang et al. [11] reported a promising prognostic value
for TSR in nasopharyngeal cancer. In a cohort of laryn-
geal SCC [22], TSR showed a predictive power for over-
all survival and recurrence-free survival. In a cohort of
laryngeal and pharyngeal squamous cell carcinoma, TSR
showed a significant association with overall survival and
response to chemotherapy [15]. In all these cohorts
(nasopharyngeal, laryngeal and pharyngeal cancers),
stroma-high tumors were associated with worse progno-
sis similar to our findings in the meta-analysis of the oral
cavity subsite (Fig. 3).
Association of TSR with clinicopathologic characteristics
Some of the published studies reported a significant asso-
ciation between TSR and clinicopathologic characteristics
of head and neck cancer including tumor stage [15], peri-
neurial invasion [12], deep invasion [10–12] and cell-in-
cell invasion [25]. In addition, TSR showed correlation
with tumor budding [15, 22] and poor lymphocytic host
response [15]. One study reported a correlation between
stroma-rich tumors and pretreatment measurements [21]
including pre-treatment positron emission tomography/
computed tomography measurements.
Discussion
Tumor stroma can influence the clinical behavior of
solid tumors [26]. The decision of multimodality treat-
ment for head and neck cancer requires identifying cases
Fig. 2 PRISMA flowchart of the search strategy and results
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at high risk of poor survival. Such identification is cur-
rently based on TNM staging and WHO grading. How-
ever, both criteria (i.e. staging and grading) rely on the
characteristics of cancer cells without consideration of
stromal features.
There is accumulated evidence indicating that
tumor stroma is one of the key elements in cancer
progression and it contains important cell types (e.g.
cancer-associated fibroblasts) that can regulate cancer
spread and influence the most fatal event, i.e. metas-
tasis, through production of growth factors and extra-
cellular matrix [27]. Tumors with high amounts of
tumor stroma can benefit from stromal growth-
promoting factors leading to a more aggressive behav-
ior and worse survival [6].
Interaction of cancer cells with the surrounding cells
of the tumor stroma has been widely studied. Epithelial
to mesenchymal transition (EMT) is an important event
during cancer invasion in which squamous cells acquire
mesenchymal properties. EMT has been linked to inva-
sive front of the tumor where cancer cells interface with
stromal cells [28]. At the histologic level, high activity of
tumor budding which reveals EMT (as it is associated
with EMT-like changes [29, 30]) has been significantly
correlated with high amount of tumor stroma in head
and neck cancer [15, 22], and colorectal cancer as well
[31]. This has been speculated as an impact of rich
stroma which facilitates EMT [15]. Furthermore, cancer-
associated fibroblasts (CAFs), which are abundant cells
and constitute a main component of the tumor stroma,
Table 2 Quality assessment of the relevant articles using Quality In Prognosis Studies (QUIPS) tool
Included studies Bias Domains








Zhang et al. 2014
(China) [11]
Low risk Low risk Low risk Low risk Low risk Low risk
Niranjan et al. 2018
(India) [10]
Low risk Low risk Low risk Low risk Low risk Low risk
Almangush et al. 2018
(Finland & Brazil) [12]
Low risk Low risk Low risk Low risk Low risk Low risk
Karpathiou et al. 2019
(France) [15]
Low risk Low risk Low risk Low risk Low risk Low risk
Karpathiou et al. 2020
(France) [21]
Low risk Low risk Low risk Low risk Moderate risk Low risk
Zhang et al. 2020
(China) [22]
Low risk Low risk Low risk Low risk Moderate risk Low risk
Dourado et al. 2020
(Brazil) [14]
Low risk Low risk Low risk Low risk Low risk Low risk
Bello et al. 2020
(Finland & Brazil) [23, 24]
Low risk Low risk Low risk Moderate risk Moderate risk Moderate risk
Mascitti et al. 2020
(Italy) [13]
Low risk Low risk Low risk Low risk Low risk Low risk
Fig. 3 Forest plots for the meta-analysis of studies evaluated the prognostic value of tumor-stroma ratio in oral cancer. a: Disease-specific survival.
b: Disease-free survival
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have been associated with induced EMT in head and
neck cancer [32]. The relationship between stromal
components (e.g. CAFs) and EMT was also reported in
other cancers which emphasize the significance of tumor
stroma in the process of EMT [33–35].
In general, it has been speculated that a high content
of tumor stroma associated with worse survival indicates
a high level of interaction between cancer cells and stro-
mal cells [36]. Moreover, tumors with a high content of
tumor stroma were associated with a poor lymphocytic
response suggesting that a strong immune response can
prevent the development of tumor stroma minimizing
aggressiveness of the tumor [15]. Furthermore, many
studies on head and neck cancer showed a significant
correlation between a high content of tumor stroma
with features of tumor aggressiveness (Fig. 1b) including
perineurial invasion [12], depth of infiltration [10–12],
cell-in-cell invasion [25], advanced stage and treatment
resistance [15]. Of note, correlation between stroma-rich
tumors and aggressive behavior has been reported in
other cancer types as well [7, 36].
Assessment of stromal-related biomarkers and stromal
characteristics has received increasing attention in recent
years. In many cancers, TSR has been identified as an
important prognostic factor [6–9]. Interestingly, a high
level of agreement between observers has been reported
in studies on head and neck cancer [10–14] as well as
on other cancers [7–9]. In addition, assessment of TSR
has been conducted using routine HE stained glass slides
and can be performed within a few minutes [16, 22].
Aiming to standardize the method of assessment of TSR,
van Pelt et al. [16] have recently introduced recommen-
dations for the assessment of TSR. For scoring of TSR
they recommended to consider the most deeply invasive
part of the primary tumor. Areas with the highest
amount of stroma are selected at low magnification (ob-
jective × 2.5 or × 5); then a stromal area which has
tumor islands/cells present at all edges of the selected
field is scored at a higher magnification (objective × 10).
In cases of heterogeneity, the highest percentage of
stroma is selected. Pelt et al. [16] further suggested using
50% as a cutoff value for dividing tumors as having low
or high stromal content. Interestingly, these recommen-
dations [16] were approved widely in the published stud-
ies of head and neck cancer using HE-stained sections,
and therefore they can be proposed as a standard
method for the evaluation of TSR in daily practice.
The current study has a few limitations including a
relatively small number of studies on each subsite and
the well-known heterogeneity in cancer behavior be-
tween the various subsites of head and neck. In addition,
we were not able to include all studies on different sub-
sites of head and neck cancers in one meta-analysis to
avoid combining heterogenous cohorts which has been
criticized previously [37, 38]. However, there is consist-
ent evidence in all published studies indicating that TSR
is a clinically relevant parameter in head and neck can-
cer. In all studies, head and neck cancers with a high
amount of stromal content were associated with worse
survival. This is in accordance with results on other can-
cers such as gastric, breast, cervical and colon carcin-
omas [6–9] suggesting a generalized nature of our
conclusion. Assessment of TSR in good quality biopsies
has been suggested recently for oral tongue cancer [24].
Conclusions
The simplicity of assessment, the inter-observer repro-
ducibility and the reliability of the prognostic value of
TSR indicate that this cost-effective prognostic param-
eter could be implemented in routine diagnostics and
clinical decision-making in head and neck cancer. Future
research should consider the assessment of TSR in
prospective studies of large cohorts of head and neck
cancer. Furthermore, a recent study has introduced
preoperative assessment of TSR in rectal cancer using
magnetic resonance imaging [39]. Such methods for pre-
operative evaluation of TSR should be widely considered
for head and neck cancer as well. Targeting the tumor
stroma of tumors with high stromal content could form
a new strategy in the management of head and neck
cancer.
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